Clovis Oncology Inc (fka CLVSQ) (CLVSQ)

[crudeoil24]

Clovis rucaparib comparison to Lynparza 'not looking so hot,' says Feuerstein
After Clovis Oncology (CLVS) announced the oral presentation of the primary efficacy and safety data from its NDA dataset for rucaparib, which is currently under priority review with FDA for the monotherapy treatment of advanced ovarian cancer in select patients, Adam Feuerstein, biotech reporter for TheStreet.com, commented on Twitter that the comparison of Clovis' data to AstraZeneca's (AZN) Lynparza are "not looking so hot." Shares of Clovis are now down over 26% in pre-market trading. Reference Link :theflyonthewall.com